Free. Unsubscribe any time.
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. filed 27 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 10 reporting owners, covering 286 transactions and 297,432 shares. None carries the SEC's AFF10B5ONE flag; all 27 name a plan in a footnote. 7 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-06-03, came 57 days after the one before it (2026-04-07) and reports 7 transactions against 14 in the filing before it.
- The sales it reports total 3,830 shares, 80 fewer than the 3,910 in the filing before it.
- Of the 10 companies the register lists beside it in its industry, 3 have more plan statements on file than it and 7 have fewer.
- Its 27 filings on file run from 2025-01-24 to 2026-06-03, and state 14 plan adoption dates, from 2024-05-10 to 2025-12-16.
Trades in ALNYLAM PHARMACEUTICALS, INC. 286
- SHARP PHILLIP A — 2025-01-23 · S · 11,250 shares
- Garg Pushkal — 2025-01-27 · S · 52,592 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 145 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 164 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 110 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 47 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 53 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 26 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 33 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 12 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 21 shares
- Fitzgerald Kevin Joseph — 2025-02-14 · S · 26 shares
Adoption dates in ALNYLAM PHARMACEUTICALS, INC. 14
- 2024-05-10 — stated in 2 filings
- 2024-08-02 — stated in 1 filing
- 2024-09-05 — stated in 1 filing
- 2024-09-11 — stated in 6 filings
- 2024-09-12 — stated in 1 filing
- 2024-11-12 — stated in 2 filings
- 2025-05-15 — stated in 1 filing
- 2025-05-27 — stated in 1 filing
- 2025-06-10 — stated in 1 filing
- 2025-08-13 — stated in 1 filing
- 2025-08-14 — stated in 5 filings
- 2025-11-12 — stated in 1 filing
Results prints in ALNYLAM PHARMACEUTICALS, INC. 7
- 2025-01-13
- 2025-07-31
- 2025-10-30
- 2026-01-12
- 2026-02-12
- 2026-04-30
- 2026-07-30
Trades before a print in ALNYLAM PHARMACEUTICALS, INC. 21
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 39 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 42 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 41 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 96 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 123 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 85 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 155 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 98 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 73 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 47 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 199 shares
- 0 days before the 2026-01-12 print — 2026-01-12 · S · Fitzgerald Kevin Joseph · 220 shares
Interval to ALNYLAM PHARMACEUTICALS, INC.’s next reported results date
How the interval and sources are counted →
- 21within 5 days
- 21within 10 days
- 0shortest, days
- 0no later print
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
- Fitzgerald Kevin Joseph 2026-01-12 · S · 0 days before the 2026-01-12 print · CSO & EVP, Head of Research
Adoption dates ALNYLAM PHARMACEUTICALS, INC. states
- 2024-05-10 in 2 filings
- 2024-08-02 in 1 filing
- 2024-09-05 in 1 filing
- 2024-09-11 in 6 filings
- 2024-09-12 in 1 filing
- 2024-11-12 in 2 filings
- 2025-05-15 in 1 filing
- 2025-05-27 in 1 filing
- 2025-06-10 in 1 filing
- 2025-08-13 in 1 filing
- 2025-08-14 in 5 filings
- 2025-11-12 in 1 filing
- 2025-11-20 in 3 filings
- 2025-12-16 in 1 filing
Filing text: “10b5-1(c) trading plan adopted by the Reporting Person on December 16, 2025”
Reported results dates on file
- 2025-01-13
- 2025-07-31
- 2025-10-30
- 2026-01-12
- 2026-02-12
- 2026-04-30
- 2026-07-30
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.